Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents
Alimentary Pharmacology & Therapeutics2021Vol. 54(3), pp. 234–248
Citations Over TimeTop 10% of 2021 papers
Reinier C A van Linschoten, Elyke Visser, Christa D. Niehot, C. Janneke van der Woude, Jan A. Hazelzet, Desirée van Noord, Rachel West
Abstract
IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.
Related Papers
- → Impact on Employee Productivity From Presenteeism and Absenteeism(2017)32 cited
- → Absenteeism, Presenteeism, and the Economic Costs of Alcohol Hangover in The Netherlands(2024)12 cited
- → Association Between Presenteeism/Absenteeism and Well-being Among Korean Workers(2020)27 cited
- → Domain-Specific Active and Sedentary Behaviors in Relation to Workers’ Presenteeism and Absenteeism(2021)6 cited
- → Introduction(2013)1 cited